A Study to Investigate the Safety and Immunogenicity of mRNA-1469 in African Participants 1 to 65 Years of Age
A Phase 1b, Observer-Blind, Placebo-Controlled Study to Investigate the Safety and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in African Participants 1 to 65 Years of Age